Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

HeartSciences Inc. - Common Stock (NQ:HSCS)

2.610 -0.050 (-1.88%)
Streaming Delayed Price Updated: 2:40 PM EDT, Mar 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about HeartSciences Inc. - Common Stock

< Previous 1 2 3 Next >
BioMedNewsBreaks — HeartSciences Inc. (NASDAQ: HSCS; HSCSW) Secures UWE As Exclusive ECG Education Reference Center
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
University of West England Adopts HeartSciences’ MyoVista Insights™ Platform and MyoVista® wavECG™ Device to Establish ECG Education and Technology Reference Center
From HeartSciences Inc.
Via GlobeNewswire
News headline image
Cibolo Health Designates HeartSciences’ MyoVista Insights™ as Endorsed ECG Management Platform for Network of 123 Independent Hospitals
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Announces Major Upgrade to User Features of MyoVista Insights Platform with Commercial Launch Version 1.1
Version 1.1 Designed to Provide Best Usability of any ECG System 
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial Results
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Announces Conference Participation and Investor Webinar
Virtual Events Include Investor Webinar and Presentation at Emerging Growth Conference 85 
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis
Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems 
From HeartSciences Inc.
Via GlobeNewswire
News headline image
Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences’ Patent Portfolio and IP Value
Patent covers estimation of measures of heart function using an ECG, which are critical in the diagnosis and early detection of heart disease 
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone
From HeartSciences Inc.
Via GlobeNewswire
News headline image
HeartSciences’ CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences Announces Launch of MyoVista Insights™ Platform and Related Early Adopter Program
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences’ AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
Innovation Value Institute Analysis Demonstrates HeartSciences’ MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction
Further expands HeartSciences extensive patent portfolio 
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences Regains Compliance with Nasdaq Listing Requirements
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio
Granted Indian Patent for its MyoVista® Wavelet Technology 
From Heart Test Laboratories, Inc.
Via GlobeNewswire
News headline image
HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG
Patent covers use of AI-ECG for any echo measure of diastolic function, which is crucial for heart screening and early detection of heart disease 
From Heart Test Laboratories, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.